Status:
RECRUITING
Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and...
Detailed Description
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic disease. Every 3 in 4 adults have diabetes in low and middle income countries. Diabetes costs about 966 billion USD dollars in total healt...
Eligibility Criteria
Inclusion
- New onset type2 diabetes mellitus diagnosed for 2 -5 years.
- Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
- Age 18 years or above.
- Both male and female.
- Provided written informed consent.
Exclusion
- Unwillingness to participate or unwillingness to give written informed consent.
- Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.
- Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
- Diabetes related complications at the time of diagnosis.
Key Trial Info
Start Date :
August 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06570980
Start Date
August 25 2023
End Date
August 30 2024
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BSMMU
Dhaka, Bangladesh, 1000